Emergent BioSolutions launches autoinjector to protect against chemical weapons attacks

Emergent BioSolutions ($EBS) just launched a military-grade intramuscular autoinjector device for self-administration of antidotes in the case of a chemical weapons attack. The device aims to provide militaries across the world with medical countermeasures to biological and chemicals threats. It has a needle that can penetrate not just skin, but soldiers' protective gear. The rollout of Emergard won't include the U.S., where the company intends to seek FDA approval. More from FierceMedicalDevices

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.